edp-938
Small moleculeexperimental
Clinical trial activity
12 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
7
Phase 2
5
Phase 3
0
Phase 4
0
Earliest trial started Dec 7, 2017 (NCT03384823)
Timeline
Indications
Mechanism of action
- RSV F-proteinINHIBITOR
RSV F-protein inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- edp-938
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06601192 | Phase 1 | Jul 15, 2024 | Enanta Pharmaceuticals |
| NCT05568706 | Phase 2 | Nov 29, 2022 | Enanta Pharmaceuticals |
| NCT04816721 | Phase 2 | Oct 31, 2021 | Enanta Pharmaceuticals |
| NCT04927793 | Phase 1 | Jun 30, 2021 | Enanta Pharmaceuticals |
| NCT04871724 | Phase 1 | Mar 12, 2021 | Enanta Pharmaceuticals |
| NCT04633187 | Phase 2 | Dec 31, 2020 | Enanta Pharmaceuticals |
| NCT04498741 | Phase 1 | Jul 8, 2020 | Enanta Pharmaceuticals, Pharmaceutical Research Associates, Inc. (PRA) |
| NCT04196101 | Phase 2 | Dec 31, 2019 | Enanta Pharmaceuticals, PPD |
| NCT03755778 | Phase 1 | Nov 29, 2018 | Enanta Pharmaceuticals, Pharmaceutical Research Associates, Inc. (PRA) |
| NCT03750383 | Phase 1 | Nov 2, 2018 | Enanta Pharmaceuticals, Pharmaceutical Research Associates, Inc. (PRA) |
| NCT03691623 | Phase 2 | Oct 31, 2018 | Enanta Pharmaceuticals, hVIVO Services Limited |
| NCT03384823 | Phase 1 | Dec 7, 2017 | Enanta Pharmaceuticals, Pharmaceutical Research Associates, Inc. (PRA) |
Showing 12 of 12 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Enanta Pharmaceuticals | For profit | 12 | 12 | 2 | 2017 |
| Pharmaceutical Research Associates, Inc. (PRA) | For profit | 4 | 0 | 1 | 2017 |
| hVIVO Services Limited | For profit | 1 | 0 | 1 | 2018 |
| PPD | For profit | 1 | 0 | 1 | 2019 |
4 organizations
Page 1 / 1